It is interesting the estimated median disease free survival for ATP1A1 intermediate, low and high expressers was 10.4, 4.8 and 1.7 years respectively [39], which demonstrates RCC patients with an intermediate ATP1A1 expression level have much longer overall survival and better prognosis than those patients with a low or high ATP1A1 expression level. Here, ATP1A1 is linked to renal cell carcinoma.